or Try an Advanced Search...

    Technical Analysis for BMEA - Biomea Fusion, Inc.

    Grade Last Price % Change Price Change
    F 6.48 3.18% 0.20
    BMEA closed down 2.18 percent on Wednesday, November 20, 2024, on 66 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BMEA trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 3.18%
    Down 3 Days in a Row Weakness 3.18%
    Down 4 Days in a Row Weakness 3.18%
    Oversold Stochastic Weakness 3.18%
    Doji - Bullish? Reversal 0.93%
    Wide Bands Range Expansion 0.93%
    Down 3 Days in a Row Weakness 0.93%
    Oversold Stochastic Weakness 0.93%
    Wide Bands Range Expansion 0.78%
    Oversold Stochastic Weakness 0.78%
    Older End-of-Day Signals for BMEA ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 9 minutes ago
    Up 3% 9 minutes ago
    Down 2 % about 3 hours ago
    Down 1% about 3 hours ago
    Up 2% about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BMEA Chart by TradingView
    Basic chart:

    Profile

    Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer

    Is BMEA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    Nov 13 We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
    Oct 30 Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
    Oct 29 Biomea Fusion GAAP EPS of -$0.91 beats by $0.04
    Oct 29 Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
    Oct 21 Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
    Oct 15 Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP...
    Oct 10 Morning Movers: Arcadium Lithium surges after deal to be acquired
    Oct 7 Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    Oct 3 Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
    See more BMEA news...

    Comments

    T

    TraderMike over 1 year ago

    I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji).  These little biotechs are always interesting after having a big pop based on some good/promising news.  The standard plan seems to be to immediately issue a secondary offering -- which BMEA did.  So now I'm looking for it to climb back above that offering price of $30 and retest the March high.

    0 Reply
    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.74
    52 Week Low 3.61
    Average Volume 840,671
    200-Day Moving Average 10.09
    50-Day Moving Average 9.45
    20-Day Moving Average 8.79
    10-Day Moving Average 7.23
    Average True Range 0.70
    RSI (14) 22.48
    ADX 35.86
    +DI 13.38
    -DI 34.72
    Chandelier Exit (Long, 3 ATRs) 10.74
    Chandelier Exit (Short, 3 ATRs) 8.15
    Upper Bollinger Bands 12.69
    Lower Bollinger Band 4.90
    Percent B (%b) 0.18
    BandWidth 88.58
    MACD Line -1.01
    MACD Signal Line -0.70
    MACD Histogram -0.3136
    Fundamentals Value
    Market Cap 224.23 Million
    Num Shares 35.7 Million
    EPS -3.33
    Price-to-Earnings (P/E) Ratio -1.89
    Price-to-Sales 0.00
    Price-to-Book 3.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.05
    Resistance 3 (R3) 7.05 6.80 6.92
    Resistance 2 (R2) 6.80 6.61 6.80 6.87
    Resistance 1 (R1) 6.54 6.48 6.42 6.54 6.83
    Pivot Point 6.29 6.29 6.23 6.29 6.29
    Support 1 (S1) 6.03 6.10 5.91 6.03 5.73
    Support 2 (S2) 5.78 5.97 5.78 5.69
    Support 3 (S3) 5.52 5.78 5.64
    Support 4 (S4) 5.52